CD274 and neoplasm: The effect of PD-L1 monotherapy on tumor progression was not tested on the 4T1 tumor model due to reported and observed adverse hypersensitivity reactions.26 Intriguingly, the combination of PD-L1 with other IO components in the hexatherapy regimen canceled PD-L1 toxicity.